Drug Profile
MHR 24
Alternative Names: Human tumour necrosis factor; n-TNF-alphaLatest Information Update: 30 Aug 2001
Price :
$50
*
At a glance
- Originator Mochida Pharmaceutical
- Developer Hayashibara; Mochida Pharmaceutical
- Class Antineoplastics; Tumour necrosis factors
- Mechanism of Action Tumour necrosis factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 30 Aug 2001 No-Development-Reported for CNS cancer in Japan (Injection)
- 30 Aug 2001 No-Development-Reported for Lymphoma in Japan (Injection)
- 30 Aug 2001 No-Development-Reported for Skin cancer in Japan (Injection)